On August 4, 2023, the Drug Enforcement Administration (“DEA”) announced plans to host two public listening sessions, scheduled to take place on September 12 and 13, 2023 at DEA’s headquarters in ...

DEA Back to Training School, DEA Bureaucrat Blocks Science While Ignoring their Own TRAINING Manual. DEA Assistant Administrators and attorney needs a summer assignment, and MMJ BioPharma Cultivation ...

Unjustified Delays: MMJ International Holdings claims that these officials have been instrumental in the multi-year delays of their application to cultivate pharmaceutical-grade marijuana, necessary ...

Broader Implications for DEA Operations This probe is not just about individual misconduct, but points to potential systemic issues within the DEA's Diversion Control Division. Critics argue that ...

The Drug Enforcement Agency's (DEA) Office of Diversion Control regulates the purchase, storage and use of controlled substances under Title 21 Code of Federal Regulations Part 1300. The Office of ...

Reform or dismantle the DEA's Diversion Control Division and transfer oversight of controlled-substance pharmaceuticals to the FDA or NIH, where science-not outdated drug war politics-guides policy.

BOSSIER CITY, La. - Agents with the Drug Enforcement Administration (DEA) closed the Bossier City CVS Pharmacy located in the 4800 block of Barksdale Boulevard at Jimmy Davis Highway Tuesday morning.

On July 24, 2023, a new final rule from the Drug Enforcement Administration (DEA) became effective, with important consequences for companies and individuals registered to manufacture, distribute, or ...

The U.S. Drug Enforcement Agency has released its notice of proposed rulemaking for a framework to permit medically necessary controlled substances without an in-person visit without violating the ...

The American Telemedicine Association released a statement on Friday saying that it applauds the Drug Enforcement Agency for posting a meeting notice on Friday that indicates that it is "openly ...

The DEA Diversion Control Problem: A Hidden Threat to U.S. Pharmaceutical Manufacturing ? Take the case of MMJ BioPharma Cultivation - despite submissions of FDA Investigational New Drug (IND) ...